Skip to contentL
Lexicon Pharmaceuticals, Inc.
L
LXRXLexicon Pharmaceuticals, Inc. Q4 2023 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$671.00K$671.00Kderivedno prior Q4 2022 on file Net Income-$49.76M-$49.76MderivedN/M vs Q4 2022 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lexicon Pharmaceuticals, Inc. · CIK 1062822 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$46,737,000N/M Operating Cash Flowderived-$50,548,000N/M Free Cash Flowderived-$50,548,000N/M Margins · derivedOperating margin-6965.3%
Net margin-7415.2%
ended Dec 31, 2023 · filed Mar 25, 2024 · 85 d after period end